RNA Manufacturing

MANUFACTURING ARTICLES

In Vivo's Biggest Threat — Comparison To Old Models
Designing mRNA For The Next Generation Of Therapeutics
mRNA’s next leap goes beyond vaccines. This piece explores how tuning sequence design, structure, and longevity enables controlled protein expression for cancer, rare disease, and regenerative uses.
Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next
Oligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.
Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026
Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond.
To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.
Striking The Right Balance: The Critical Discussions Driving The mRNA Industry's Next Chapter
Now, I cannot claim that I or any of the panelists at CASSS have or had access to a real crystal ball that will show us the future. However, what did come through these discussions loud and clear is that the future of our industry must include “balance.” Here, I’ll unpack a few ways the theme of “balance” presented itself — and no doubt will continue to present itself in the future — as well as how the panelists see us achieving this necessary balance.

MANUFACTURING VIDEOS

Considerations To Better Understand/Mitigate Raw Material Variability

In this Bioprocess Online Live panel discussion featuring John Stubenrauch, Ph.D., Chief Operations Officer at Nutcracker Therapeutics, and Hari Pujar, Ph.D., Chief Operating Officer at Tessera, explore the impact of and how to potentially mitigate issues posed by raw material variability.

The Potential Of RNA Exon Editing With Ascidian Therapeutics' Romesh Subramanian, Ph.D.

Cell & Gene: The Podcast Host, Erin Harris, welcomes Romesh Subramanian, Ph.D., CEO of Ascidian Therapeutics, a Boston-based biotech focused on rewriting RNA to the pod. During the episode, Subramanian defines RNA exon editing, and they discuss the differences between RNA exon editing and gene editing. With current programs in ophthalmology, neurological and neuromuscular disorders, as well as rare diseases, Subramanian explains the overwhelming potential of RNA exon editing.

Robust And Cost-Effective mRNA Capping

Master the essential strategies for cost-effective and robust mRNA capping at industrial scale. Learn how to successfully evaluate new materials and optimize your synthesis process for maximum efficiency and yield.

The Price of Progress: Unlocking Cost Efficiencies in mRNA-LNP Production

In this final segment of an Advancing RNA Live discussion, panelists April Sena, Tyler Goodwin, and Adi Nair share the most meaningful and manageable improvements the industry can be making today to upstream and downstream processes to drive down mRNA-LNP COGS.In this final segment of an Advancing RNA Live discussion, panelists April Sena, Tyler Goodwin, and Adi Nair share the most meaningful and manageable improvements the industry can be making today to upstream and downstream processes to drive down mRNA-LNP COGS.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs

Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.
Discussing mRNA: Challenges And Opportunities For Scale-Out And Optimization

In a recent Cell & Gene Live event, experts explored challenges surrounding raw materials – both quality and supply – as well as the importance of achieving more efficient scale-out and turnaround times for mRNA production.
Use Of Filtration Plates For Purification Of DNAs For Sequencing Library Preparation

Discover how we examined a DNA sample purification method employing 96-well filter plates as an alternate to organic extraction.
New To mRNA Manufacturing? Considerations For Starting

Explore considerations for starting mRNA manufacturing related to the following topics: DNA template, mRNA product - IVT, mRNA product - purification, LNP encapsulation, and fill-finish.
Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow

We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.
Quality Control In IVT RNA Workflow

Accurate sizing and purity checks are essential in IVT RNA workflows. Explore how automated electrophoresis improves QC efficiency and ensures RNA integrity for downstream applications.
Understanding The Microfluidic Platforms For Scaling Nanoparticle Production

Learn about the benefits of microfluidics for nanoparticle production over traditional methods as well as scaling nanoparticle production for clinical or industrial use.

More Manufacturing Resources

MANUFACTURING ARTICLES

MANUFACTURING VIDEOS

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

MANUFACTURING SOLUTIONS